See the DrugPatentWatch profile for apremilast

Apremilast, a medication used to treat conditions such as psoriasis, psoriatic arthritis, and Behçet's disease, is currently undergoing various clinical trials to further evaluate its safety and efficacy. According to DrugPatentWatch.com, as of 2021, there are several ongoing or completed clinical trials investigating apremilast's potential in various therapeutic areas [1].

One of the ongoing clinical trials, NCT04169369, is evaluating the efficacy and safety of apremilast in combination with topical therapy for the treatment of moderate-to-severe plaque psoriasis in adolescent patients [2]. Another trial, NCT03924380, is assessing the efficacy and safety of apremilast in participants with active Behçet's disease [3].

Furthermore, a completed trial, NCT03336731, investigated the efficacy and safety of apremilast in patients with moderate-to-severe hidradenitis suppurativa [4]. Although the results of this trial have not been published yet, it indicates the continuous exploration of apremilast's potential applications.

In summary, apremilast is currently being evaluated in various clinical trials for its efficacy and safety in treating different conditions, such as plaque psoriasis, Behçet's disease, and hidradenitis suppurativa. These trials aim to provide further insights into apremilast's potential therapeutic benefits and its role in the treatment of various inflammatory diseases.

Sources:
[1] DrugPatentWatch.com - Apremilast
[2] ClinicalTrials.gov - A Study to Evaluate the Efficacy and Safety of Apremilast in Adolescent Participants With Moderate-to-Severe Plaque Psoriasis (PALACE 9)
[3] ClinicalTrials.gov - A Study to Evaluate the Efficacy and Safety of Apremilast in Participants With Active Behçet's Disease (ADVISE)
[4] ClinicalTrials.gov - A Study to Evaluate the Efficacy and Safety of Apremilast in Participants With Moderate-to-Severe Hidradenitis Suppurativa (UNLOCK)